Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

September 14, 2016

Study Reveals How Mesothelioma Cells Become Resistant to Resveratrol, Chemotherapy Combo

News

Combining the platinum chemotherapeutic drug Platinol (cisplatin) with the plant-based compound resveratrol increased cell death of malignant mesothelioma cells grown in the lab, but the effectiveness of the treatment varied ... Read more

June 14, 2016June 14, 2016

High Levels of Immune Checkpoint Seen to Improve Survival in Mesothelioma Patients

News

High levels of the T-cell immune checkpoint CTLA-4 improved survival in patients with malignant pleural mesothelioma, according to research published in the journal Cancer Immunology, Immunotherapy. The study also raises the possibility that a ... Read more

May 5, 2016May 5, 2016

Experience of Surgical Team Key Factor in Pleural Mesothelioma Care, Doctors Stress

News

Surgery plans a vital role in the care of malignant pleural mesothelioma, researchers from Baylor College of Medicine state, stressing that such operations should be restricted to experienced surgeons with excellent track ... Read more

April 29, 2016April 29, 2016

CA125 Levels in Mesothelioma Patients May Be Biomarker of Overall Survival and Chemotherapy Response

News

Chinese researchers reported that levels of CA125 — a serum marker used to monitor certain cancers — could aid in predicting overall survival and chemotherapy response in people with diffuse malignant mesothelioma. The ... Read more

April 13, 2016April 13, 2016

Radiotherapy May Trigger Mesothelioma, But Study Considers Risk to Be Minuscule

News

Radiotherapy used to treat solid cancers increases the risk of developing mesothelioma as a secondary cancer, according to a study published in the journal Cancer Medicine. The risk, however, is ... Read more

April 11, 2016April 11, 2016

Mesothelioma Study Suggests a Cancer-Promoting Pathway Could Be Redirected to Fight Disease

News

Malignant pleural mesothelioma patients who have high levels of the signaling factor AKT1 have a worse prognosis, researchers reported in the journal Oncotarget. Blocking the signaling pathway, however, boosts the ... Read more

April 5, 2016April 5, 2016

Pleural Mesothelioma and Its Possible Link to Inflammatory Macrophage MIF Continues to Baffle

News

The inflammatory macrophage migration inhibitory factor (MIF) might affect the development of malignant pleural mesothelioma. A study into the factor’s effect on cells derived from different mesothelioma cell types and stages, however, ... Read more

April 1, 2016April 1, 2016

SV40 Virus Infection Might Contribute to Malignant Mesothelioma Development

News

Researchers have previously suggested that simian virus 40 (SV40) is associated with malignant pleural mesothelioma. A study now reported that the virus was present in 20 percent of a group of ... Read more

March 23, 2016March 23, 2016

Drug Prevents Pleural Effusion, an Often Deadly Complication of Malignant Mesothelioma, in Mouse Study

News

One of the most troublesome, and potentially fatal, complications of malignant mesothelioma is the accumulation of liquid in the pleural cavity — so-called malignant pleural effusion. A study showed that the ... Read more

March 15, 2016March 15, 2016

Researchers Develop New Mouse Model of Malignant Mesothelioma to Study Interaction in Cancer Cells, Immune System

News

Researchers from San Raffaele Hospital in Milan, Italy, created and extensively characterized a new mouse model of malignant mesothelioma. The model allows the researchers to study the interactions between cancer cells and ... Read more